Adaptive Biotechnologies Corp (nasdaq:ADPT) Share Price

Company Profile

Business description
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
Contact
1165 Eastlake Avenue East
SeattleWA98109
USA
T: +1 206 659-0067
https://www.adaptivebiotech.com
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2026
Employees
624

Recommended

Discounted exit raises investor concerns.

Yingqi Tan, CFA | 21 September 2026

The data and AI company is one of the world’s strongest private companies, but a PitchBook report says it’s unattractive at the current price.

Jacob Robbins | 21 September 2026

Morningstar analysts’ take on the takeover for this undervalued industrial player.

Esther Holloway | 20 September 2026

Index	Last price	Change	% Change
All Ordinaries	8,951.00	31.90	0.36%
CAC 40	8,171.48	32.54	0.40%
DAX 40	25,694.01	119.00	0.47%
Dow JONES (US)	52,163.97	115.14	0.22%
FTSE 100	10,746.24	7.23	0.07%
HKSE	25,087.75	45.04	0.18%
NASDAQ	27,227.41	105.32	0.39%
Nikkei 225	65,018.95	882.70	1.38%
NZX 50 Index	13,875.48	54.28	0.39%
S&P 500	7,779.50	14.80	0.19%
S&P/ASX 200	8,757.80	25.90	0.30%
SSE Composite Index	3,952.13	2.22	0.06%